Compare FTK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | ACET |
|---|---|---|
| Founded | 1985 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 77.3M |
| IPO Year | 1997 | 2017 |
| Metric | FTK | ACET |
|---|---|---|
| Price | $20.42 | $7.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $20.00 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 241.4K | 83.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $169.54 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $10.96 | $0.46 |
| 52 Week High | $20.73 | $9.05 |
| Indicator | FTK | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 70.00 | 50.58 |
| Support Level | $15.20 | $7.50 |
| Resistance Level | N/A | $8.68 |
| Average True Range (ATR) | 1.30 | 0.53 |
| MACD | 0.34 | -0.10 |
| Stochastic Oscillator | 87.77 | 42.82 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).